Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for resisting myocardial ischemia-reperfusion injury

A reperfusion injury and anti-myocardial ischemia technology, applied in the field of biomedicine, can solve problems such as inaccurate results and complicated operations, and achieve the effects of reducing content, inhibiting cell apoptosis, and inhibiting cardiomyocyte apoptosis

Pending Publication Date: 2020-11-13
GUANGDONG XINBAO PHARMA TECH CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these surgical treatment methods have obvious effects, the operation is relatively complicated; while the above-mentioned drugs are easy to use and have shown good pharmacological effects in animal experiments, but the results in clinical trials are not accurate.
At present, there is no report in the prior art that Xinbao Pill has anti-myocardial ischemia-reperfusion injury.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for resisting myocardial ischemia-reperfusion injury
  • Medicine for resisting myocardial ischemia-reperfusion injury
  • Medicine for resisting myocardial ischemia-reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Evaluation of the effect of Xinbao Pill on the viability of h9c2 cardiomyocytes

[0046] The operation method is as follows: take h9c2 cardiomyocytes grown in the logarithmic phase, inoculate them in 96-well culture plates at 5000 / well, overnight, after the cells grow well, add Xinbao Wan containing different concentrations (0, 4, 8, 16 , 32, 64, 128, 256, 512, 1024 μg / mL) complete DMEM medium, stop the culture after 24 hours of culture. Then add 100 μL of 0.5 mg / mL MTT solution, continue to cultivate for 4 hours, discard the medium, add 150 μL DMSO to shake and mix, place on a microplate reader, and measure the absorbance value at a wavelength of 490 nm. The result is as figure 1 Shown: Xinbao Pills did not produce any toxicity to h9c2 cardiomyocytes at concentrations below 1024 μg / mL.

Embodiment 2

[0048] Evaluation of the Protective Effect of Xinbao Pills on Hypoxia-reoxygenation h9c2 Cardiomyocytes

[0049] The operation method is as follows: take h9c2 cardiomyocytes growing in the logarithmic phase, inoculate them in 96-well culture plates at 5000 / well, overnight, and after the cells grow well, replace them with Xinbao Wan containing different concentrations (0, 10, 60, 240, 720 μg / mL) and the positive control drug diazoxide (100 μM) in a sugar-free serum-free medium, cultured in an anaerobic device for 6 hours, then changed to a completely normal DMEM medium, and continued to culture for 18 hours before stopping the culture. Then add 100 μL of 0.5 mg / mL MTT solution, continue to cultivate for 4 hours, discard the medium, add 150 μL DMSO to shake and mix, place on a microplate reader, and measure the absorbance value at a wavelength of 490 nm. The result is as figure 2 Shown: Xinbao Wan can significantly inhibit the hypoxia-reoxygenation-induced decline in the viabi...

Embodiment 3

[0051] Evaluation of the protective effect of Xinbao Pills on rat myocardial ischemia-reperfusion injury induced by ligation of the left anterior descending coronary artery, including the following:

[0052] (1) Animal grouping: Adult male Sprague-Dawley (SD) rats (WM: 250-280 g) were used for in vivo experiments. Four rats were housed in each cage, and a 12:12h light-dark cycle was performed in an SPF animal room at 22±2°C and humidity. Animals were allowed free access to standard rodent chow and distilled water. 24 rats were randomly divided into 3 groups, 8 in each group: the first group was SHAM group (sham operation group), normal saline (i.p.); the second group was MI / R group (myocardial ischemia-reperfusion injury group) , normal saline (i.p.); the third group is MI / R+Xinbao Wan group (MI / R+XBW) (180mg / kg, i.p.). Male SD rats were subjected to ligation of the left anterior descending coronary artery. Xinbao pills were dissolved in normal saline and administered intrag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medicine for resisting myocardial ischemia reperfusion injury. The medicine comprises Xinbao pills. The invention creatively discovers that the Xinbao pill can be used as a medicine for resisting myocardial ischemia-reperfusion injury; the Xinbao pill can also be used for preparing a medicine for resisting myocardial ischemia reperfusion injury, has a very strong protection effect on hypoxic reoxygenation h9c2 myocardial cells in vitro, and can inhibit h9c2 cell injury caused by hypoxic reoxygenation; the area of myocardial ischemia-reperfusion injury rat heart infarction induced by coronary artery anterior left descending branch ligation and the content of CK-MB can be remarkably reduced in vivo, and myocardial cell apoptosis is inhibited; meanwhile, expression ofheart tissue apoptosis related protein can be inhibited, the proportion of anti-apoptosis protein is increased, and expression of cell autophagy related protein Beclin-1 and LC3II is inhibited. The invention provides a theoretical basis for researching a treatment strategy of myocardial ischemia-reperfusion injury, and provides an embedding point for preparing a new medicine for resisting myocardial ischemia-reperfusion injury.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a new drug application of Xinbao Wan, in particular to a drug for resisting myocardial ischemia-reperfusion injury. Background technique [0002] Acute myocardial infarction (AMI) is a disease with high risk and high mortality rate, and reperfusion is a commonly used method in clinical practice. After reperfusion quickly restores blood supply, it can effectively save the surviving myocardial cells, reduce the size of the infarct area, maintain the systolic function of the left ventricle, and block the occurrence of heart failure. And structural abnormalities, thus exacerbating cardiac tissue damage, that is, ischemia-reperfusion injury (ischemia reperfusion injury, IRI). Therefore, preventing myocardial ischemia-reperfusion injury (Ischemia reperfusion injury, IRI) is a clinical event that cannot be ignored in the treatment of AMI. In order to reduce myocardial ischemia-reperf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/81A61P9/10A61K35/32A61K35/55A61K35/65A61K31/045
CPCA61K31/045A61K35/32A61K35/55A61K35/65A61K36/258A61K36/54A61K36/714A61K36/81A61P9/10A61K2300/00
Inventor 蔡荣钦刘中秋陈婷程媛媛吴丽琼林琼英胡宏军陈思璇刘嘉铭杨莹
Owner GUANGDONG XINBAO PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com